Malignant oligodendroglioma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Malignant oligodendroglioma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety of Aminolevulinic Acid with Ultrasound Therapy for Patients with Newly Diagnosed High-Grade Glioma Before Surgery and Standard Treatment https://clinicaltrials.eu/trial/study-on-the-safety-of-aminolevulinic-acid-with-ultrasound-therapy-for-patients-with-newly-diagnosed-high-grade-glioma-before-surgery-and-standard-treatment/ Wed, 29 Apr 2026 14:58:16 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-aminolevulinic-acid-with-ultrasound-therapy-for-patients-with-newly-diagnosed-high-grade-glioma-before-surgery-and-standard-treatment/ This clinical trial is focused on studying a type of fast-growing brain tumor known as high-grade glioma. The trial will explore the safety of a treatment that combines a substance called 5-aminolevulinic acid (5-ALA) with a method called sonodynamic therapy (SDT), which uses ultrasound waves. The treatment is intended for patients who have been newly diagnosed with high-grade glioma and are scheduled for surgery to remove the tumor, followed by standard therapy.

The purpose of the study is to evaluate how safe and tolerable this new treatment is for patients. Participants will receive the treatment in the form of an oral solution, which means it is taken by mouth. The study will monitor patients for any side effects or adverse reactions for a period of 28 days after the treatment is administered. This monitoring will include regular check-ups and tests to ensure the safety of the participants.

Throughout the study, changes in the tumor will be observed using MRI scans, which are imaging tests that help doctors see inside the body. The study will also look at how the treatment affects the tumor at a cellular level. This trial aims to provide valuable information about the potential of 5-ALA combined with SDT as a treatment option for high-grade glioma.

]]>